CA-WILSHIRE/XTP
29.8.2024 15:01:32 CEST | Business Wire | Press release
Wilshire Advisors LLC (“Wilshire”), a leading global financial services firm, today announced that it has joined forces with XTP Implementation Services (“XTP”), a tech-enabled and data-driven specialist focused on improving transparency, reducing risk, enhancing investment governance, and increasing net returns for institutional investors globally. Through this partnership, which was effectuated by an acquisition of XTP by Wilshire, with simultaneous reinvestment in Wilshire by former XTP shareholders, XTP will continue to operate independently under its existing leadership team and brand. Financial terms of the transaction were not disclosed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240828886722/en/
XTP is a market leader in cost transparency analytics, with a 20-year history of serving public and private investors, including pension funds, insurance companies, sovereign wealth funds, investment consultants, outsourced chief investment officers, endowments and foundations, and family offices. With more than $3 trillion in assets analyzed across 10,000 portfolios in North America and Europe, XTP helps its clients reduce investment-related costs and risks while enhancing governance. Combining deep industry experience and proprietary software, benchmarking databases, and forensic capabilities allows XTP to identify optimization potential across the investment value chain of public and private market portfolios. XTP clients benefit from a risk-free increase in net returns.
Andy Stewart, CEO at Wilshire, said: “We are excited to partner with XTP and bring its cost and risk-reduction services to our institutional clients, which will benefit from the power of its sophisticated insights and solutions. Throughout our discussions, it was clear that Wilshire and XTP share a holistic, client-centric approach that seeks to align our success with that of our clients. On behalf of Wilshire, I extend a warm welcome to the talented XTP team and look forward to collaborating for the benefit of our combined client base.”
Philipp Henrich, Founder and CEO at XTP, said: “We welcome our partnership with Wilshire, whose solutions, clients, and geographic footprint are complementary to ours. By joining forces, we have the opportunity to leverage the resources of a global service provider with a very strong presence in North America. This will enable us to offer our capabilities to an expanded client base while continuing to provide our valued, long-standing customers personalized, mission-critical support. We could not be more optimistic about this new, bright chapter for XTP with Wilshire alongside us.”
Jason Schwarz, President and Deputy CEO at Wilshire, said: “Institutional investors worldwide are more focused than ever on efficiency and transparency, seeking to better understand, disclose, and manage the true costs of their investments. XTP has an impressive 20-year track record and unmatched ability to identify cost and risk-reduction opportunities and translate those insights into enhanced returns. By bringing together XTP’s proprietary capabilities and Wilshire’s multifaceted platform, we will be even better positioned to empower clients with solutions that address their top concerns and deliver even more value.”
Solomon Partners and Kirkland & Ellis LLP served as financial advisor and legal advisor to Wilshire, respectively. XTP shareholders were advised by DLA Piper.
About Wilshire
Wilshire is a leading global financial services firm and trusted partner to approximately 500 leading institutional investors and financial intermediaries. Our clients rely on us to improve investment outcomes for a better future. Wilshire advises on over $1.4 trillion in assets and manages over $121 billion in assets as of March 31, 2024. Wilshire is headquartered in the United States with offices worldwide. More information on Wilshire can be found at www.wilshire.com.
About XTP
XTP is a specialist consultant focusing on transparency, cost, and risk. XTP actively supports large institutional asset owners globally in turning data into measurable results. By creating full cost transparency in public and private market portfolios XTP assures contract compliance, eliminates process inefficiencies and operation risks, and optimizes costs without changing the existing investment set-up. More information on XTP can be found at www.xtp-group.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828886722/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release
Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit
Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse
Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig
PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom